Medlive Technology Co Ltd
Medlive Technology Co Ltd provides advertising and marketing services, primarily operating in the health care technology sector.
Business. Medlive Technology Co Ltd (2192.HK) is a Hong Kong-headquartered company listed on the Hong Kong Stock Exchange. The firm operates within the Advertising & Marketing industry, providing digital healthcare marketing and advertising services. As specific segment and geographic breakdowns are not disclosed, the company is described at the industry level. Its primary business activity involves facilitating connections between healthcare providers and patients through digital platforms.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Medlive Technology Co Ltd (2192.HK) is a Hong Kong-headquartered company listed on the Hong Kong Stock Exchange. The firm operates within the Advertising & Marketing industry, providing digital healthcare marketing and advertising services. As specific segment and geographic breakdowns are not disclosed, the company is described at the industry level. Its primary business activity involves facilitating connections between healthcare providers and patients through digital platforms.
Medlive Technology Co Ltd has a basic and diluted share count of 740,114,125, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available in the current dataset, making it difficult to compare the company's performance against industry benchmarks or preferred metrics. Without these figures, an assessment of operational efficiency or capital returns is not feasible.
The company's revenue concentration and geographic exposure are not disclosed in the available data. This lack of information limits the ability to assess the diversification of its revenue streams or the risks associated with geographic concentration.
Growth trajectory is not quantified in the current dataset, and no numeric deltas are provided for the current or next fiscal year. Analysts have assigned a mean price target of 11.73 CNY and a median price target of 11.40 CNY, with a mean recommendation of 1.50, indicating a generally positive outlook.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data. The company is currently rated as having low dilution risk, but the absence of detailed financial disclosures limits the ability to fully evaluate potential risks.
Recent events and filings are not detailed in the available data, so no specific recent developments can be cited. Analysts have issued a total of 2 strong-buy and 2 buy recommendations, with no hold or sell ratings, suggesting a favorable market sentiment.
- Medlive Technology Co Ltd has no immediate dilution pressure based on current share counts.
- Analysts have a generally positive outlook, with a mean price target of 11.73 CNY and a median price target of 11.40 CNY.
- Liquidity risk could not be assessed due to missing balance-sheet data.
- The company's profitability and return metrics are not available, limiting performance comparisons.
- Revenue concentration and geographic exposure are not disclosed, making diversification assessment difficult.
- Growth trajectory and future performance are not quantified in the current dataset.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥642.2M, +15,0% YoY; Operating income +5,7% YoY.
- ▍Revenue ¥642.2M, +15,0% YoY
- ▍Operating income +5,7% YoY
- ▍Net income +6,1% YoY
- ▍Free cash flow +16,8% YoY
- ▍Net margin 52.1%
Revenue ¥558.5M, +35,5% YoY; Operating income +34,6% YoY.
- ▍Revenue ¥558.5M, +35,5% YoY
- ▍Operating income +34,6% YoY
- ▍Net income +30,1% YoY
- ▍Free cash flow +40,5% YoY
- ▍Net margin 56.4%
Revenue ¥412.0M, +31,2% YoY; Operating income +87,0% YoY.
- ▍Revenue ¥412.0M, +31,2% YoY
- ▍Operating income +87,0% YoY
- ▍Net income +106,5% YoY
- ▍Free cash flow −10,2% YoY
- ▍Net margin 58.8%
Revenue ¥314.1M, +10,4% YoY; Operating income +92,4% YoY.
- ▍Revenue ¥314.1M, +10,4% YoY
- ▍Operating income +92,4% YoY
- ▍Net income +188,8% YoY
- ▍Free cash flow +372,0% YoY
- ▍Net margin 37.4%
Revenue ¥284.4M; Operating income ¥70.5M.
- ▍Revenue ¥284.4M
- ▍Operating income ¥70.5M
- ▍Net margin 14.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,47 |
| Revenue | —no estimate | —no estimate | 749,0M CNY |
| Operating income | —no estimate | —no estimate | 286,3M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Medlive Technology Co Ltd Market data — financials · 2026-05-26
- Medlive Technology Co Ltd Market data — analyst estimates · 2026-05-26